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ABSTRACT 
Although mutation occurs randomly in nature and is passed randomly between bacterial species, 
the misuse and overuse of antibiotics in modern medicine has selected for antibiotic resistant 
organisms, resulting in an epidemic of antibiotic resistant infections. Used extensively in former 
Soviet Union countries with success, Western researchers have begun considering phage therapy 
for treatments, however it must be subjected to rigorous clinical trials before it can be approved 
by the FDA as a treatment method in North America (Gill et al. 2010; Abhilash et al. 2009).  
 
In this study, phage screening was performed on eight MDR bacterial strains provided from 
LifeLabs and Royal Inland Hospital in Kamloops, B.C.: E. coli 15-102, 15-124, and 14-318; 
Micrococcus luteus; Methicillin Resistant Staphylococcus Aureus (MRSA) 1 and 2; Serratia 
marcescens; and Mycobacterium smegmatis. One non-resistant E. coli strain known to be killed 
by phages found in Kamloops sewage was used as a positive control. Seven water samples and 
one non-water sample were used in this experiment as a source of phages. Water samples were 
obtained from the Kamloops Sewage Treatment Plant, the Domtar pulp mill run-off, the Pacific 
Ocean, Bisaro Anima Cave, and alkaline ponds around Kamloops. The non-water sample was 
created from mixing dirt from Abbotsford, B.C. with sterile water. An additional enriched water 
sample was made through the incubation of broth culture, nutrient broth, and sewage water 
overnight at 37°C in an attempt to select for more strain-specific phages (Prescott et al. 2005). In 
addition, sterile water was used in the protocol as a negative control.  
 
The successfulness of each phage screening trial was measured through the formation of plaques, 
which developed after plating the Multiple Drug Resistant (MDR) bacteria, molten agar, and 
phages for confluent growth on nutrient agar (Prescott et al. 2005). Of all the bacteria and 
environmental water samples, plaques only developed for the E. coli 14-318 strain using sewage 
water from the Kamloops Sewage Treatment Center. Using phage screening against these MDR 
bacteria allowed us to see that MDR pathogens present in our community are treatable with a 
potentially more beneficial and successful method to antibiotics.  
 
 
Thesis Supervisor: Dr. Naowarat Cheeptham 
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INTRODUCTION 
 
BACKGROUND AND RATIONALE 
Importance of Phage Therapy  
Due to decades of extensive misuse and overuse of antibiotics in modern medicine, antibiotics that 
were once effective against pathogenic bacteria are now no longer sufficient because of rapid 
evolution and mutation of resistant bacterial species. Although novel antibiotics targeting MDR 
bacteria can be developed, pathogens ultimately end up becoming resistant to such drugs (Carlton 
1999). To break this vicious cycle, phage therapy, which has been used extensively in former 
Soviet Union countries with success, is being reconsidered as a treatment method by Western 
researchers, who have exclusively relied on antibiotics to date. However, acceptance of this 
method has been difficult to obtain, and phage therapy must be subjected to rigorous clinical trials 
before it can be approved by the FDA as a treatment method (Gill et al. 2010; Abhilash et al. 
2009). 
 
Phage Therapy History 
Phages were first discovered by British microbiologist Felix Twort in 1915, and later by French-
Canadian microbiologist Felix d’Hérelle in 1917. Although Twort did not pursue his discovery, 
d’Hérelle investigated the nature and mechanism of phages as a therapeutic agent, and established 
phage therapy centers in the U.S., France, and Soviet Georgia (Carlton 1999). D’Hérelle’s first use 
of phage screening was on French troops with severe hemorrhagic dysentery in July 1915, where 
he made bacterium-free filtrates of patients fecal samples and incubated them with isolated 
Shigella strains from the patients. He observed the appearance of clear plaques on agar plates, 
which he proposed were caused by a virus capable of parasitizing bacteria. These phages were 
later used in phage therapy trials in 1919 on hospital patients with severe dysentery, and after a 
single dose, the patients fully recovered (Sulakvelidze et al. 2001). The use of bacteriophages as 
therapeutic agents was later used extensively during World War Two, particularly by Soviet 
doctors to treat wound infections of troops on the battlefield. However the discovery of penicillin 
in 1928 caused a sharp decline in phage research in the West, which chose to prioritize treatment 
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of bacterial infections with antibiotics, leaving only the former Soviet Union countries still 
developing and utilizing phage therapy (Abedon et al. 2011).  
 
Classification of Phages 
Phages are classed into 13 different families according to their morphology, presence or absence 
of an envelope or lipid, and type of nucleic acid. Approximately 96% of phages are composed of 
an icosahedral head and tail and have double stranded DNA as their genome and are termed “tailed 
phages.” Tailed phages are further classified by their morphological features into three families: 
Myoviridae, which possess a contractile tail and contain 93 species, including phages KVP20, 
KVP40, KVP241, and T-even; Siphoviridae, which possess a long non-contractile tail and contain 
313 species, including phages ΦMR11 and λ; and Podoviridae, which possess an extremely short 
tail and contain 50 species, including T7 phages. The other 4% of phages are classified as cubic, 
filamentous, or pleomorphic and contain double stranded or single stranded DNA or RNA 
(Matsuzaki et al. 2005).  
 
Bacteriophage Life Cycle  
Phages are viruses that infect and lyse specific bacteria through interacting with bacterial 
membrane receptors, disrupting bacterial metabolism, and eventually causing the cell to lyse after 
replicating their DNA inside of the bacterial host cell. (Gill et al. 2010; Abhilash et al. 2009). 
Phages can be divided into two groups according to their life cycle: lytic phages, which insert their 
DNA into bacteria and self-proliferate, leading to bacterial lysis, and lysogenic phages, which have 
an additional lysogenic cycle where their DNA is incorporated into the host genome and replicated 
as part of the host genome without lysing the cell. However, under environmental stress, such as 
changes in temperature, pH, and nutrients, the lytic cycle can be triggered, lysing the cell. As some 
lysogenic phages have toxic genes in their genome which can become incorporated into the 
bacterial genome, lytic phages are the most suitable therapeutic candidates. Alternatively, 
pseudolysogeny can occur, in which the phage genome enters the cell but cannot enter the lytic or 
lysogenic cycle. This typically occurs in nutrient-deprived conditions, when bacterial hosts cannot 
support DNA replication, and the phage genome will persist as a preprophage until nutrition is 
restored, at which point it can enter the lytic or lysogenic cycle (Figure 1; Feiner et al. 2015:used 
with permission).  
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Figure 1. The lytic, lysogenic, and pseudolysogenic cycles. a. The lytic bacteriophage cycle, in 
which the phage replicates using host machinery and lyses the cell; b. The lysogenic cycle, where 
the phage genome is incorporated into the host chromosome as a prophage and persists in a 
dormant state until environmental stressors trigger the lytic cycle to commence; c. 
Pseudolysogeny, in which phage genome fails to replicate or establish itself as a prophage, 
occurring typically in nutrient-deprived conditions (Feiner et al. 2015, used with permission). 
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Mechanism of Bacteriolysis by Phages  
The first step of bacteriolysis is phage infection, through which phages adsorb to a receptor on the 
bacterial surface, which is typically a protein or sugar. Phages generally only adsorb to specific 
bacterial strains or species, not across multiple species or genera, which makes bacteriophage 
therapy as a targeted therapeutic treatment so beneficial. After phage adsorption, phage DNA is 
injected into host cytoplasm and is either integrated into the host chromosome or replicated by 
host machinery and packaged into capsids, which are created during the late stage of phage 
infection. Tails are then attached to the DNA-filled head. The new phages then lyse the cell through 
the protein interactions of lysin, which degrades peptidoglycan, and holin, which form holes in the 
cell membrane, exposing the peptidoglycan layers to lysin. The released phages infect other 
bacterial cells following this, leading to lysis of the entire bacterial population. (Figure 3; 
(Matsuzaki et ali. 2005: used with permission) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Phage induced bacteriolysis: (1) Phage adsorption and DNA injection; (2) Phage  DNA 
replication; (3) head and tail production; (4) holin and lysin synthesis; (5) DNA packaging; (6) 
complete phage assembly; (7) lysis of cell wall and release of phages; (8) circularization of phage 
DNA; (9) integration of phage DNA into host genome via lytic cycle (Matsuzaki et al. 2005, used 
with permission).  
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Bacteriophage Screening and Therapy Research 
 
Pseudomonas aeruginosa  
Vinodkumar et al. targeted 28 multidrug-resistant Pseudomonas aeruginosa strains in 1,647 
septicemic mice using bacteriophages over a period of five years. Phages were isolated from raw 
sewage at a municipal sewage treatment plant after incubating sewage, nutrient broth, and P. 
aeruginosa at 58°C for 30 minutes in a water bath, following which a few drops of chloroform 
were added, the mixture was centrifuged, and the supernatant was filtered through a 0.22 µl filter. 
The effectiveness of bacteriophage activity on P. aeruginosa was confirmed in vitro through 
placing phage isolate in wells on a P. aeruginosa lawn for 24 hours at 37°C, using sterile distilled 
water as a control. The phage strain used was effective against 74% of the P. aeruginosa strains. 
The 28 multidrug-resistant strains were resistant to almost all types of antibiotics, including β 
lactamases, and were used to introduce a fatal infection into the mice. A single injection of the 
phage strain administrated 45 minutes after the P. aeruginosa injection was sufficient to rescue 
100% of the animals, and an injection when the mice were moribund was successful in rescuing 
approximately 50% of the mice (Vinodkumar et al. 2008).    
 
A clinical trial by Wright et al. 2009 also tested phages against multiple-drug resistant P. 
aeruginosa in 24 patients with chronic otitis. Researchers found that the treatment patients showed 
significantly lower pathogenic P. aeruginosa levels 42 days after treatment compared to the 
placebo group and that no treatment-related adverse effect was reported. These results are 
indicative of phage therapy success in human clinical trials (Wright et al. 2009).  
 
Enterococcus faecium  
Biswas et al. 2002 used phage therapy on Vancomycin-resistant Enterococcus faecium infections 
in mice. Colonization of the gastrointestinal tract by Vancomycin-resistant E. faecium has become 
endemic in many hospitals and can lead to endocarditis, so a reliable treatment method is essential. 
Phages were isolated from municipal sewage through centrifugation and removal of the 
supernatant, following which the supernatant was added to precipitate in 10% polyethylene glycol, 
dissolved in SM buffer, and extracted with chloroform. This processed sewage was mixed with E. 
faecium and incubated for 20 minutes at 37°C, before being mixed with top agar and poured on 
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agar plates and incubated overnight. Phages present in plaques were isolated and used in mice 
given a potentially fatal E. faecium injection. Phage injection 45 minutes after pathogen injection 
resulted in the rescue of 100% of the animals, and phage injection into moribund animals resulted 
in approximately 50% of the mice being rescued (Biswas et al. 2002).  
 
Escherichia coli  
Chibani-Chennoufi et al. collected diarrhea-associated Escherichia coli samples from pediatric 
diarrhea patients and environmental water samples, and isolated phages from fecal samples 
through centrifugation and filtration of the supernatant through a 0.45 µl filter. Phage plaque assays 
were successfully performed, and purified phages were given to mice with regular and ampicillin-
resistant E. coli infections through drinking water. The results showed that some of the intestinal 
E. coli strains were lysed successfully, however, other strains were not. In particular, E. coli present 
in gut flora were only minimally affected by oral phage application, indicating that the phages 
were specific enough to only work against specific E. coli strains (Chibani-Chennoufi et al. 2004).  
 
Benefits of Bacteriophage Therapy  
As phages are composed mostly of nucleic acids and proteins, they are much less toxic than 
antibiotics, and phage therapy is seen as a superior method to antibiotics as it is much more specific 
and should be less likely to cause side effects or negative harm to the beneficial normal flora of 
the host (Abedon et al. 2011; Loc-Carillo et al. 2011; Matsuzaki et al. 2005). In addition, phages 
are reportedly very successful against bacteria that construct biofilms composed of a 
polysaccharide matrix that antibiotics cannot penetrate (Abhilash et al. 2009).  
 
Bacteriophages are also notably more successful at completely killing the target bacteria species 
in comparison to antibiotics, and are also capable of increasing in number in an area specifically 
where the bacteria species is located, therefore phages themselves contribute to establishing the 
phage dose during phage therapy. Because of this, only a single dose of phages is generally 
required for treatment (Loc-Carillo et al. 2011).  
 
Phages are also successful against extremely resistant bacteria strains. In addition to resistance to 
regular antibiotics, bacterial strains have been found to contain enzymes such as carbapenemases 
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and Extended-Spectrum Beta-Lactamases (ESBL), which further add to the broad resistance of the 
strains to treatment. Carbapenemases are β-lactamases which are capable of hydrolyzing 
carbapenems, cephalosporins, monobactams, and penicillins (Queenan et al. 2007). As multiple 
drug resistance (MDR) to antibiotics is easily passed through a plasmid during bacterial 
conjugation, carbapenems have been used to counteract MDR resistance, however this has led 
bacterial strains to develop resistance to carbapenems as well (Currie 2012). ESBLs are also β-
lactamases found only amongst Gram negative bacteria, and mediate resistance to extended-
spectrum cephalosporins and monobactams, but do not affect cephamycins or carbapenems (CDC 
2010). Infections from bacteria which possess these enzymes renders antibiotic treatment highly 
unsuccessful, illustrating the importance of the development of an alternative treatment method, 
such as phage therapy.  
 
In addition, phages are easily applied in the form of topical treatments and injections, and are 
versatile with regards to formulation development, as they can be used in combination with 
antibiotics or with other phage strains to increase the success of infection treatment (Loc-Carillo 
et al. 2011).  
 
Drawbacks of Bacteriophage Therapy  
The ideal phage is obligately lytic, stable in storage conditions and temperatures, subject to 
appropriate safety studies, specific to the target bacteria, and ideally, fully sequenced to ensure 
that it carries no toxin genes, which are difficult conditions to meet (Loc-Carillo et al. 2011). Even 
if a specific phage that is effective is found, it must be able to enter the lytic cycle to be used in 
treatment, as lysogenic phages will lay dormant until environmental stress is experienced by the 
host cell. Phages must also be able to be stored for long periods of time after they are isolated 
without breaking down, typically at -20°C (Prescott et al. 2005). Another issue is getting approval 
to put phage therapy on clinical trials so that it can be accepted as a treatment method in the west. 
Former Soviet countries do not face this problem, but for phage therapy to be put into use and 
approved by the FDA, rigorous clinical trials must be undergone. In addition, changing the western 
mindset to accept using viruses to treat infections presents another challenge. Phages only 
attacking a narrow host range is another problem, as isolating phages specific-enough for certain 
bacteria may take a lot of time and energy. Because of this, multiple phages may need to be 
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combined in a dosage in a so-called “phage cocktail”  in order to most effectively target the bacteria 
(Loc-Carillo et al. 2011). Finally, phages have been known to contain toxin genes and regulate 
virulence in bacteria, so sequencing phages before they are put to therapeutic use is essential to 
ensuring the treatment will be beneficial (Wagner et al. 2002).   
 
Bacteriophage Therapy in Combination with Other Treatment Methods  
Although phages are used exclusively as a treatment method in Russia, countries like Poland use 
phages in combination with other treatment methods, in order to maximize treatment potential 
(Carlton et al. 1999). Although resistance to common antibiotics has become an issue, researchers 
are still finding novel antibiotics to which bacteria do not have resistance genes, which can 
potentially be used in combination with phages to ensure that all pathogenic bacteria are killed 
(Huff et al. 2004). Another novel treatment method exclusive to antibiotics and phage therapy is 
using clay to kill bacteria, as exhibited by the Kisameet Clay in the Heiltsuk First Nation territory 
in British Columbia, which has been shown to have antibacterial activity against MDR 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species (Behroozian et al. 2016). Phages could 
potentially be used in combination with this clay to give the most effective treatment possible for 
bacterial infections, much like the combination of antibiotics and phages.  
 
SOURCES OF BACTERIOPHAGES 
 
Water Samples Used  
Using water samples from the Kamloops Sewage Treatment Plant, Domtar, the Pacific Ocean, 
Bisaro Anima Cave, alkaline ponds, and the non-water dirt sample in this project as a source of 
phages could have allowed for the discovery of novel phages which could have been extremely 
successful in lab. For instance, sewage contains many potentially pathogenic bacteria, such as 
Escherichia coli and Enterobacter aerogenes, which suggests that phages capable of successfully 
attacking these potentially dangerous and rapidly-evolving bacteria may also be present in the 
sewage sample from the Kamloops Sewage Treatment Center (Beaudoin et al. 2007). Likewise, 
cave water and Domtar runoff present extreme habitats, seeing as bacteria are forced to grow in 
energetically unfavourable and nutrient-limited conditions, and may host many novel and diverse 
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bacteria species and their respective phages, which may be effective against other MDR bacteria 
(Barton et al. 2007). In addition, alkali pond water is extremely acidic and selects for resistant and 
adaptive bacteria such as E. coli. We can speculate that if E. coli is present excessively in alkali 
pond water, phages associated for E. coli are likely present as well (Parhad et al. 1974). Seawater 
has also been found to contain over 150 different isolates of bacteriophages and phages are shown 
to exceed bacterial concentration in seawater by a factor of 10, therefore seawater should have 
been a rich source of phages (Børsheim 1993). Soil was also speculated to contain bacteriophages 
effective against MDR bacteria, as soil contains many bacteria that can become pathogenic to 
humans, and an average of 1.5 x 108 g-1 phages, which is equivalent to 4% of the total population 
of bacteria (Ashelford et al. 2003).  
 
The creation of an enrichment water sample was also attempted through the incubation of broth 
culture, nutrient broth, and filtered sewage water overnight at 37°C. Through exposing the 
bacteriophages present in the water sample to only one bacterial strain, it was projected that more 
successful phage screening trials would occur (Biswas et al. 2004; Chibani-Chennoufi et al. 2004; 
Prescott et al. 2005; Wright et al. 2009; Vinodkumar et al. 2008).  
 
The successfulness of each environmental water sample was measured through the formation of 
plaques, which develop after plating the MDR bacteria, molten agar, and environmental water for 
confluent growth (Prescott et al. 2005). The development of plaques on the E. coli strains would 
further signal that bacteria possessing carbapenemases and ESBLs and are essentially untreatable 
can be treated successfully using phages. All plaques were sent to sequence the bacteriophages 
present to determine if novel phages had been found.  
 
OBJECTIVE 
The main objective of this project was to screen bacteriophages (bacteria-infecting viruses) from 
extreme habitats that specifically target the multiple drug resistant (MDR) bacteria. In particular, 
this experiment focused on the isolation of phages from local water samples, namely sewage water 
samples from the Kamloops Sewage Treatment Plant, and their effectiveness against MDR E. coli 
obtained from LifeLabs. We aimed to develop insight into the correct process, optimal 
concentrations, and proper conditions needed for phage isolation, and determine whether 
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successful bacteria-specific phages were capable of being screened, grown, and used against MDR 
bacteria.  
 
The null hypothesis was that the MDR bacteria would be unaffected by bacteriophage screening 
and live regardless of the inoculation with phages. 
MATERIALS AND METHODS 
 
WATER SAMPLE COLLECTION 
Water samples were obtained aseptically in sterile bottles from the Kamloops Sewage Treatment 
Plant, Domtar (three samples taken at 1.4 days, 2.3 days, and 3.3 days into the purification process, 
with the sample taken at 3.3 days being the final treated effluent), the Pacific Ocean (Bamfield, 
B.C.), Bisaro Anima Cave, and alkaline ponds. A water sample was also created from mixing dirt 
from Abbotsford, B.C. with sterile water. All samples were stored at 4°C until use. 
 
WATER SAMPLE FILTRATION FOR BACTERIOPHAGE ISOLATION 
Water samples were either syringe-filtered or pressure-filtered through a 0.22 µm filter to remove 
bacterial particles, ensuring only phages were present. Samples containing a lot of particulate and 
debris were first filtered with a 0.45 µm filter, and then a 0.22 µm filter. In one trial, an enrichment 
water sample was created through the combination of nutrient broth, E. coli 14-318 bacterial 
culture, and sewage water incubated overnight at 37°C to promote the growth of strain-specific 
phages, before being filtered through a 0.22 µm filter. The soil sample from Abbotsford was mixed 
with sterile water and let stand for 24 hours. It was then filtered using a 0.22 µm filter.  
 
CONTROLS 
Positive and negative controls were used in the experiment. For the negative control, sterile water 
was plated in combination with the MDR bacteria, expecting that the bacteria would exhibit 
confluent growth and no plaque development would occur. The positive control involved plating 
the environmental water samples with a non-MDR strain of E. coli that was previously shown to 
be killed by phages present in the Kamloops Sewage Treatment Centre water sample, expecting 
that plaques would develop in this situation.   
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SEQUENCING 
A plate containing plaques from sewage water which was successful against E. coli 14-318 was 
sent to GENEWIZ, Inc, in Seattle, USA, for sequencing. Following unsuccessful sequencing, new 
plates were sent to the University of Texas for sequencing. Both times, the standard laboratory 
procedure was repeated to ensure plaque formation, following which the fresh plate was wrapped 
in parafilm and shipped via express post on ice. 
 
SAFETY PRECAUTIONS 
The experiments were undergone in the laboratory in a biosafety cabinet so as to not contaminate 
other areas of the lab with the water samples and the MDR bacteria. All contaminated equipment 
was labelled and kept together and all samples were labelled and stored in an isolated area in the 
walk-in fridge. Proper biosafety training was also undergone in accordance with the requirements 
for Laboratory safety 2.  
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PROCEDURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Overview of experimental procedure outlining the isolation and purification of 
bacteriophages from water samples, growth of bacteria in nutrient broth, and combination of phage 
water, bacteria, and molten agar on nutrient agar plate.  
 
MDR Bacteria Preparation  
Bacteria strains were confirmed to be multiple-drug resistant through a streak plate test on nutrient 
agar plates infused with tetracycline. Once resistance was confirmed, bacterial species were 
inoculated in nutrient broth overnight, shaking at 37°C, and then placed in the fridge to preserve 
cell density.  
 
Isolation and purification of phage strains  
Water samples were stored in the fridge at 4°C until ready for use. Samples were first filtered 
through a 0.45 µm filter to remove bacteria and excess debris if needed, followed by a 0.22 µm 
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filter, to leave only bacteriophages present in the water samples. The environmental water was 
stored at 4°C in fridge until needed. 
 
In vitro confirmation of bacteriophage activity  
In a test tube, 0.5 mL environmental water and 0.5 mL broth culture bacteria were mixed with 2.5 
mL molten nutrient agar warmed to approximately 55°C, which was hot enough to pour easily but 
not hot enough to kill the bacteria, and then poured evenly onto nutrient agar plate. This step was 
also repeated with dilutions of 0.9 mL environmental water and 0.1 mL bacteria, but no significant 
differences in plaque formation were seen between the two dilutions. Petri plate lids were 
immediately placed onto plates to avoid contamination, and the plates were inverted and incubated 
at 37°C for 24 hours.  
 
After incubation, the plates were checked for the presence of plaques. If plaques were found, the 
procedure was repeated again to ensure legitimate plaque formation, and the plates were wrapped 
in parafilm and sent via express post to be sequenced.  
RESULTS 
The combination of top molten agar, broth culture, and filtered environmental water samples was 
first attempted using the water samples from the Kamloops Sewage Treatment Center, the Pacific 
Ocean, and Domtar, however no plaques formed. The same protocol was repeated using strain-
specific environmental water samples through the incubation of broth culture, nutrient broth, and 
environmental water overnight before filtering for isolated phages, however no plaque 
development was observed. Furthermore, plaque formation was not seen using water samples from 
Bisaro Anima Cave, alkali ponds, or the soil sample (Table1).  
 
A more crude water sample was obtained from the Kamloops Sewage Treatment Centre, from 
which phages capable of successfully killing the MDR bacteria were only found. The only bacterial 
strain that developed plaques from this water sample was the E. coli 14-318 strain at both a 5:5 
dilution and a 9:1 dilution of sewage water to broth culture (Table 2). A sewage water enrichment 
sample was prepared through the inoculation of broth culture in sewage water and nutrient broth 
overnight to induce strain-specific phages and was successful against the E. coli 14-318 strain. For 
the 5:5 broth dilution, 31 plaques were found, ranging in sizes from 1 mm to 5 mm and for the 5:5 
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sewage dilution 22 plaques were observed, sized 2 mm to 7mm. For the 9:1 broth dilution, 52 
plaques were found ranging in size from 0.5 mm to 11 mm, and for the 9:1 sewage dilution, 39 
plaques were noted from 1mm to 7 mm (Table 3). Overall, no significant difference was noted in 
the successfulness of phages between those present in the enrichment water and those in the 
sewage water, indicating that the enrichment water did not contain more strain-specific phages, 
and that the phages were equally as successful at lysing bacterial cells.   
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Table 1. The resistance, possession of carbapenemase and ESBL, and plaque presence observed 
of the MDR bacteria used in this project.  
 
Strain Resistance Carbapenamase ESBL Plaque 
Presence 
E. coli 15-102 Ampicillin1 + + - 
E. coli 15-124 Ampicillin2 + + - 
E. coli 14-318 Ampicillin3 + + + 
Micrococcus luteus TET (tetracycline-30 µg) U5 U - 
MRSA TET (tetracycline-30 µg) U U - 
MRSA  U U - 
Serratia Tetracycline4 U U - 
Mybacterium 
smegmatis 
SXT (sulfamethoxozole-23.75 
µg and trimethoprim-1.25 µg) 
U U - 
Control : E. coli None U U + 
1Ampicillin, Amoxicillin/Clavulanic Acid, Piperacillin/Tazobactam, Cefalotin, Cefazolin, 
Cefoxitin, Cefixime, Ceftazidime, Ceftriaxone, Ertapenem, Meropenem, Amikacin, Gentamicin, 
Tobramycin, Ciprofloxacin, Tetracyclin, Nitrofurantoin, Trimethoprim/Sulfamethoxazole, 
2Ampicillin, Amoxicillin/Clavulanic Acid, Piperacillin/Tazobactam, Cefalotin, Cefazolin, 
Cefoxitin, Cefixime, Ceftazidime, Ceftriaxone, Ertapenem, Meropenem, Ciprofloxacin, 
Tetracyclin, Trimethoprim/Sulfamethoxazole, 
3Ampicillin, Amoxicillin/Clavulanic Acid, Piperacillin/Tazobactam, Cefalotin, Cefazolin, 
Cefoxitin, Cefixime, Ceftazidime, Ceftriaxone, Ertapenem, Meropenem, Amikacin, Gentamicin, 
Tobramycin, Ciprofloxacin, Tetracyclin, Nitrofurantoin, Trimethoprim/Sulfamethoxazole, 
4Tetracycline, Gentamicin, Nitrofurantoin, Ceftriaxone, Tobramycin, Amikacin, Cefixime, 
Meropenem, Ertapenem 
5Unknown 
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Table 2. The water sample location and presence of plaques when water samples had been plated 
with MDR bacteria and molten agar.  
Water Sample Location Plaque Presence 
Alkali Ponds No 
Bisaro Anima Cave No 
Domtar (three different samples) No 
Kamloops Sewage Treatment Plant Yes1 
Sea Water (Bamfield, B.C.) No 
Soil Sample (Abbotsford, B.C.) No 
1 Worked against E. coli 14-318 and control E. coli  
 
Table 3. The different water sample (enriched or regular sewage) to bacterial broth dilutions and 
the number and size of plaques present.   
Water Sample Dilution Number of Plaques Plaque Size 
500 µL Enrichment : 500 µL Bacteria 31 1 mm - 5 mm 
500 µL Regular : 500 µL Bacteria 22 2 mm - 7 mm 
900 µL Enrichment : 100 µL Bacteria 52 0.5 mm - 11 mm 
900 µL Regular : 100 µL Bacteria 39 1 mm - 7 mm 
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Table 4. Additional resistance of E. coli 14-318 to beta lactams, aminoglycosides, quinolones, 
tetracyclines, furanes, and trimethoprim/sulfonamides.  
 
Antibiotic Types Resistance 
Beta Lactams ESBL, including carbapenemase 
Aminoglycosides Gentamicin, Tobramycin, Netilmicin 
Quinolones All 
Tetracyclines All 
Furanes All 
Trimethoprim/Sulfonamides All 
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Figure 4. Plaque presence after plating bacterial strain E. coli 14-318 with molten agar and sewage 
water and sewage broth samples in different concentrations: 1. 500 µL sewage water to 500 µL 
bacterial culture; 2. 500 µL enrichment sewage to 500 µL bacterial culture; 3. 900 µL sewage 
water to 100 µL bacterial culture; and 4. 900 µL enrichment sewage to 100 µL bacterial culture.  
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DISCUSSION 
 
The absence of plaques found from plating a combination of top agar, broth culture, and filtered 
environmental water samples prompted the need for the growth and isolation of more strain-
specific phages. This led to the creation of an enrichment broth through the inoculation of water 
samples, broth culture, and nutrient broth overnight before filtering the water for isolated phages.  
 
The continued absence of phages inferred that either phages were not present in the water samples, 
or that phages specific enough to kill the MDR and control bacteria were not present. The latter 
point is supported, as the phages present in sewage water were successful against both the E. coli 
14-318 strain and the control E. coli strain, however not against the E. coli  15-102 and 15-124 
strains, indicating the specificity required for phages to attack a cell, even amongst bacteria of the 
same species (Chibani-Chennoufi et al. 2004). In addition, as sewage contains human excrement, 
which is rich in E. coli and other human pathogens, it was expected that phages capable of killing 
human pathogens would be present in the samples. However, the other water samples used came 
from environments that are not necessarily rich in human pathogens, which could account for the 
lack of phage specificity and plaque development.  
 
A more crude sewage water samples was then put through the protocol, both as a standard filtered 
water sample and also as an enriched water sample, which was prepared through the incubation of 
broth culture, nutrient broth, and sewage water overnight. Sewage from sewage treatment centers 
is a rich source of phages and is used extensively in protocols in previous research as it contains a 
wide variety of human gut bacteria, potentially containing phages which specifically target human 
pathogens like the MDR bacteria used in the study. Due to the wide variety of bacteria present in 
sewage, many different bacteriophages could be present in one sample, which increases the 
chances of more MDR bacteria being targeted by bacteriophages. (Biswas et al. 2002; Vinodkumar 
et al. 2008; Wright et al. 2009). Phages have also been isolated from patient feces in the previous 
research, however only using feces from one subject likely narrows the amount of phages isolated 
(Chibani-Chennoufi et al. 2004).  
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Plaque presence was observed in both the E. coli 14-318 strain and the control E. coli strain, and 
there was not a noticeable difference in the number of plaques between the regular sewage sample 
and the enriched sample, indicating that the enriched sample did not improve specificity. These 
results were not expected, as enriched environmental water samples are used in most studies for 
phage screening, and were proposed to be more specific and successful against pathogens. Plaque 
size, however, differed considerably on the plates, ranging from 0.5 mm to 11 mm, potentially 
indicating that different phages were present (Biswas et al. 2004; Chibani-Chennoufi et al. 2004; 
Prescott et al. 2005; Wright et al. 2009; Vinodkumar et al. 2008).  
 
The last water samples tested were from Bisaro Anima Cave and alkaline ponds, however no 
plaques developed after plating. Soil was also used as a phage source after being mixed with sterile 
water and filtered, but no plaques developed after plating. Along with the first water samples 
tested, it was inferred that phages did not exist in the water samples or that phage screening was 
not successful against the specific MDR bacteria. Compared to sewage water samples, which 
contain human excrement containing gut microbiota and potentially pathogens, extreme water and 
soil samples such as the Bisaro Amina Cave, alkali ponds, and soil samples used in this project are 
not necessarily exposed to the same species and strains of bacteria that associate with humans. 
Although the presence of E. coli in alkali ponds and soil samples has specifically been supported 
in previous studies, perhaps the phages present in these samples were not specific to the MDR E. 
coli used in this project (Børsheim 1993; Parhad et al. 1974). This postulation is supported as 
phages effective against one MDR E. coli strain were not effective against all of the MDR E. coli 
strains used, further illustrating the importance of specificity in phage screening. Indeed, the need 
for species- and strain-specific phages hinders the development of phage therapy as a therapeutic 
treatment method as such phages can be difficult to isolate and discover, rendering some bacterial 
infections untreatable. Although antibiotics negatively affect good gut microbiota, they are 
designed to kill all bacteria without needing specific parameters or specificity to do so, making 
antibiotics a broader and more effective treatment method theoretically. However, in the case of 
MDR bacteria, where antibiotics are useless, the time and energy spent finding phages specific to 
these bacteria is extremely important and critical to the treatment of these bacteria (Loc-Carillo et 
al. 2011).   
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Plates with E. coli 14-318 plaques were sent to be sequenced at GENEWIZ, Inc. Although a phage 
primer was used, phage genomes do not have the same conserved regions that bacterial genomes 
have, therefore the primer did not bind well to the E. coli 14-318 genome and the sequencing 
results were inconclusive (Hattful 2008). The plaques are now being sequenced at the University 
of Texas.  
 
The results of this experiment were significant, as phages capable of killing MDR E. coli through 
phage screening were found to be present in local sewage and successful in multiple trials. 
Furthermore, the E. coli 14-318 strain possesses beta lactamases and is resistant to 
aminoglycosides, quinolones, tetracyclines, furanes, trimethoprims, and sulfonamides, which 
make antibiotic treatment nearly impossible. Therefore, the discovery of an alternative method to 
kill this bacteria strain is significant as no other common treatment method has been successful. 
In addition, these results contribute positively to phage therapy research and clinical trials in North 
America, and continued results of these trials will hopefully result in the FDA approving phage 
therapy as an alternative treatment method.  
 
For future expansion of this research, more environmental water samples should be collected, 
including sewage and fecal samples from other cities and countries, considering feces is rich in 
phages specific to human pathogens and diverse sample sites could provide a wider range of 
phages. Phages could also be isolated from compost, landfills, and soil samples which are exposed 
to human wastes.  In addition, more E. coli strains should be collected and screened to observe 
which strains the sewage phages are effective against, in order to further investigate the specificity 
of bacteriophages amongst a species.  
 
Although there are downsides to phage therapy, such as the requirement for phages to be obligately 
lytic, stable in storage, safe in experimental studies, matched to specific bacteria, and fully 
sequenced to ensure they won’t pass on toxicity, phage therapy is an effective therapeutic treatment 
method to treating bacterial infections, and could be used against bacteria which are resistant to 
antibiotics. This method has been used extensively in the former Soviet Union countries with 
success and is currently being researched extensively in the United States before it can be placed 
in clinical trials to be approved by the FDA as a treatment method. Along with phages being more 
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specific to target bacterial species and not having a negative effect on beneficial host microbiota, 
only one dose is needed for treatment as phages regulate their numbers based on the amount of 
target bacteria present and phages can be combined easily with other treatment methods, such as 
antibiotics and clay, to ensure the most effective and efficient treatment of bacterial infections. 
Although time, money, and energy need to be put into phage research and clinical trials, approval 
of this treatment method may be crucial for western medicine to counter the epidemic of antibiotic 
resistance. The benefits of phage therapy clearly outweigh the disadvantages.  
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